Table 7. Multivariate analysis of factors predictive of progression-free survival and overall survival.
| Risk Factor | PFS |
Risk Factor | OS |
||||
|---|---|---|---|---|---|---|---|
| Hazard ratio | 95% CI | p | Hazard ratio | 95% CI | p | ||
| Patients with B-PET (n = 47) | Patients with B-PET (n = 47) | ||||||
| PET (SUVmax ≥ 15.1 vs. <15.1) | 1.239 | 0.442–3.472 | 0.683 | B-PET (SUVmax ≥ 15.1 vs. <15.1) | 6.671 | 1.413–31.501 | 0.017 |
| PET (MTV ≥ 16.11 vs. <16.11) | 2.313 | 0.827–6.472 | 0.110 | PET (MTV ≥ 16.11 vs. <16.11) | 1.209 | 0.303–4.824 | 0.788 |
| PET (TLG ≥ 45.90 vs. <45.90) | 6.940 | 1.413–34.12 | 0.017 | PET (TLG ≥ 45.90 vs. <45.90) | 8.632 | 1.090–68.336 | 0.041 |
| B symptoms (Yes vs. No) | 1.010 | 0.341–2.991 | 0.986 | Ann Arbor Stage (III/IV vs. I/II) | 1.100 | 0.291–4.148 | 0.889 |
| KPI score (3–4 vs. 0–2) | 1.536 | 0.592–3.988 | 0.378 | KPI score (3–4 vs. 0–2) | 1.852 | 0.515–6.665 | 0.346 |
| Patients with I-PET (n = 34) | Patients with I-PET (n = 34) | ||||||
| I-PET (positive vs. negative) | 5.355 | 1.646–17.424 | 0.005 | I-PET (positive vs. negative) | 5.596 | 1.159–27.015 | 0.032 |
| B symptoms (Yes vs. No) | 3.690 | 1.012–13.451 | 0.048 | Ann Arbor Stage (III/IV vs. I/II) | 4.333 | 1.081–17.371 | 0.038 |
| LDH level (>245 vs. ≤245) | 1.902 | 0.600–6.027 | 0.274 | KPI score (3–4 vs. 0–2) | 1.211 | 0.175–8.397 | 0.846 |
| KPI score (3–4 vs. 0–2) | 1.491 | 0.401–5.542 | 0.551 | ||||
| Patients with E-PET (n = 28) | Patients with E-PET (n = 28) | ||||||
| E-PET (positive vs. negative) | 3.926 | 1.189–12.963 | 0.025 | E-PET (positive vs. negative) | 4.740 | 1.127–19.939 | 0.034 |
| IPI score (2–5 vs. 0–1) | 2.374 | 0.687–8.201 | 0.172 | IPI score | 1.124 | 0.233–5.421 | 0.884 |
| KPI score (3–4 vs. 0–2) | 1.044 | 0.250–4.366 | 0.953 | KPI score (3–4 vs. 0–2) | 2.135 | 0.457–9.978 | 0.335 |
B-PET, baseline PET/CT; I-PET, interim PET/CT; E-PET, end-of-treatment PET/CT; PFS, progression-free survival; OS, overall survival; SUVmax, maximum standardized uptake value; WBMTV, whole-body metabolic tumour volume; WBTLG, whole-body total lesion glycolysis; KPI, Korean prognostic index.